Drug Detail

Information about BIIB-022

Generic Name
IND	BIIB-022
Brand Name (US)
Manufacturer	Biogen Idec
Drug Type	monoclonal antibody
Delivery	Intravenous
Approval Status	Discontinued?
Indications
Overall Strategy	GIST cell based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor

A recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R recombinant monoclonal antibody BIIB022 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of downstream pathways; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.